Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study. Breast Cancer Res Treat. 2020 Aug;182(3):689-697. Jordan, Nicole Vincent et ...
参考文献 [1] Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER-2-positive advanced gastric or gastro-oesophageal junction cancer ...
[3]Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. [4]Yelena Y. Janjigian, ...
[3]Bang YJ, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97. [4]Yelena Y. Janjigian, ...
在最近一项研究中，来自美国斯坦福大学药学学院的研究团队在Nature Cancer上发表题为“Spatial proteomic characterization of HER2-positive breast tumors through neoadjuvant therapy predicts response”的空间蛋白组学研究，证实了经过一个周期HER2靶向治疗后的空间蛋白组的变化信息可以很好地帮助预测临床获益，即最终会达到...
[1] Bachelot T, Romieu G, Campone et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013 Jan;14(1):64-71. doi: 10.1016/S1470-2045(12)70432-1. Epub...
Me´nard S, Balsari A, Casalini P, et al: HER2-positive breast carcino- mas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8:520-525, 2002Menard S,Balsari A,Casalini P, et al.HER-2-positive breast carcinomas as a particular subset with peculiar clinical ...
【3】 Yelena Y Janjigian, Steven B Maron, et al.,First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial, Lancet 2020:821-831.
of Clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer [J]. 癌症通讯(英文), 2019, 39(1): 31.[4] BANG Y J, VAN C E, FEYEREISLOVA A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive ...
7.Lin, N. U., Pegram,M.Sahebjam,S.Ibrahim,N.Fung,A.Cheng, A.&Kumthekar,P. (2021). Pertuzumab Plus High-Dose Trastuzumab in Patients With Progressive Brain Metastases and HER2-Positive Metastatic Breast Cancer: Primary Analysis of a ...